Video

Dr. Kane on Genetic Testing for Prostate Cancer

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses the impact of genetic testing on patients with prostate cancer.

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses the impact of genetic testing on patients with prostate cancer.

Genetic testing for patients with prostate cancer can have a broad impact on who needs to be screened and who can benefit from screening. Many times, when patients come in for screening, they don’t know their family history, explains Kane.

The genomic risk that might be inherited in your germline could influence the type of prostate cancer a patient could have and how sensitive that prostate cancer is to different types of treatment, states Kane.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center